Liver fatty acid-binding protein • MicroRNA • Steatosis • Nonalcoholic fatty liver disease Abstract Background/Aims: Liver fatty acid-binding protein (FABP1) is a key regulator of hepatic lipid metabolism. MicroRNAs (miRNAs) are thought to be involved in nonalcoholic fatty liver disease (NAFLD), and the underlying mechanism is largely unclear. We investigated whether miRNAs influence hepatocyte steatosis by regulating the FABP1 gene. Methods: Candidate FABP1-targeting miRNAs were evaluated using luciferase reporter assay. FABP1 expression was measured using western blotting and quantitative reverse transcription-PCR. Intracellular lipid accumulation was measured based on Oil Red O staining and intracellular triglyceride content. Hepatocyte injury was evaluated based on culture supernatant levels of alanine aminotransferase, aspartate aminotransferase, and intracellular adenosine triphosphate, and mitochondrial membrane potential. Results: Dicer1 knockdown significantly elevated FABP1 expression. In total, 68 miRNAs potentially targeting FABP1 were selected; of these, miR-3941, miR-4517, and miR-4672 directly targeted the FABP1 3ʹ untranslated region. Mimics of the three miRNAs substantially repressed FABP1 expression at translational level and led to HepG2 cell resistance to steatosis and cell injury induced by free fatty acids mixture, which rescue of FABP1 overexpression reversed. Conclusion: Our findings identify a novel mechanism by which miRNAs protect against hepatocyte steatosis and injury by downregulating FABP1 expression.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is deemed the hepatic manifestation of metabolic syndrome, the characteristics of which include insulin resistance, dyslipidemia, hypertension, and type 2 diabetes [1, 2] . The occurrence of NAFLD is mainly attributed to the accumulation of fat in the liver, and cirrhosis can follow; it is irreversible and may eventually develop into hepatocellular carcinoma [3, 4] . However, many factors are involved in the complex process of liver steatosis; its pathogenesis is largely unknown. Recent cell studies and genetically modified mouse models have demonstrated that hepatic lipid metabolism and steatosis are crucially affected by peroxisome proliferator-activated receptor (PPAR)-c coactivator 1α and 1β [5, 6] , receptor-interacting protein 140 [7] , and liver fatty acid-binding protein [8] (FABP1 or L-FABP).
FABP1 belongs to a multi-gene FABP family of 14-15-kDa cytoplasmic proteins involved in the uptake, transport, and metabolism of cellular long-chain fatty acids and other lipid ligands [9] . The human FABP1 gene is localized in the p11.2 region of chromosome 2 [10] . FABP1 is abundant in the cytosol of liver parenchymal cells [11, 12] and represents approximately 0.2% of the total cytosolic proteins in the human hepatoblastoma cell line HepG2 [13] . Similar to its family members, FABP1 plays a central role in intracellular fatty acid transport and utilization [14] and is also involved in modulating mitosis [15] , cell growth, and differentiation [16] . In vitro cell models and in vivo mouse models have indicated that FABP1 plays an important role in regulating hepatic lipid metabolism. HepG2 cell studies have indicated that FABP1 overexpression markedly increased the rate of fatty acid uptake. In contrast, FABP1 antisense RNA expression decreased fatty acid uptake significantly [17] . FABP1 −/− mice fed a high-saturated fat, high-cholesterol "Western" diet were protected against diet-induced obesity and hepatic steatosis, reflecting an alteration in the kinetics of saturated fatty acid utilization [18, 19] .
MicroRNAs (miRNAs) are single-stranded, 19-25-nucleotide long, non-coding RNAs that are involved in the regulation of numerous biological processes by base-pairing, usually imperfectly, to the 3ʹ untranslated region (UTR) of a target mRNA, inhibiting it post-transcriptionally and occasionally leading to mRNA degradation [20, 21] . miRNAs can regulate the metabolism-related genes potentially involved in NAFLD pathogenesis. For example, the most highly expressed hepatic miRNA is miR-122, a regulator of cholesterol and fatty acid metabolism [22, 23, 24] ; miR-10b regulates cellular steatosis levels through PPARα [24] . Furthermore, mitochondrial dysfunction [25] , oxidative stress [26] , insulin resistance [27] , and inflammation [28] , generally considered critical components of NAFLD, are regulated by several miRNAs. miRNAs regulating FABP1 expression have not been identified. Here, we determined whether miRNAs can regulate FABP1 gene expression and participate in FABP1-associated hepatic steatosis.
Materials and Methods

Cell culture and clinical specimens
HepG2 cells (HB-8065, ATCC, Manassas, VA) were maintained in Dulbecco's modified Eagle medium (Invitrogen, Carlsbad, CA) supplemented with 10% (v/v) fetal bovine serum (Invitrogen). Surgically resected adjacent normal liver tissues were obtained from 24 hepatocellular carcinoma (HCC) patients who underwent surgical resection. All samples were immediately frozen and stored in liquid nitrogen. The study protocol had all the appropriate approvals by the institutional review board and regulatory authorities. All patients had given informed and written consent.
Bioinformatics analysis
Possible FABP1-targeting miRNAs were predicted using four miRNA target-prediction tools: TargetScan, PicTar, miRanda, and RNA22. Bioinformatics analysis of the FABP1 3ʹ UTR and all predicted miRNAs were considered potential targets for further analysis.
Construction of expression vectors
We constructed the pcDNA3.1-FABP1 vector by ligating the FABP1 cDNA into the HindIII and XhoI sites of pcDNA3.1-Hygro (+) (Invitrogen). FABP1 cDNA was amplified using reverse transcription-PCR from mRNA
Luciferase reporter constructs and oligonucleotide transfection
Wild-type and mutant miRNA-targeted FABP1 3ʹ UTR were synthesized chemically by BoShang Biotech (Shanghai, China) and cloned downstream of a promoter-driven dual-luciferase reporter plasmid pmirGLO (Promega, Madison, WI). Table 2 shows the mutation sites.
The Dicer1 small interfering RNA (siRNA) mix and negative control (NC) siRNA were obtained from Santa Cruz Biotechnology (Santa Cruz, CA); Mimics and inhibitors of miR-3941, miR-4517, and miR-4672 were synthesized by RiboBio (Guangzhou, China). Oligonucleotide transfection was performed using X-tremeGENE siRNA Transfection Reagent (Roche Diagnostics, GmbH, Mannheim, Germany).
miRNA screening and luciferase assay For the miRNA screening, HepG2 cells were seeded in 12-well plates. After 24-h incubation, the cells were co-transfected with 1 μg pmirGLO reporter plasmid carrying wild-type or mutant FABP1 3ʹ UTR and 100 pmol NC or mimic. The luciferase activity was measured 48 h after transfection using the dual-luciferase reporter assay (Promega) according to the manufacturer's recommendations. Luminescence was measured using a luminometer (Orion II Microplate Luminometer, Berthold Detection Systems, Pforzheim, Germany). All assays were performed in triplicate at minimum.
RNA extraction and quantitative reverse transcription (RT)-PCR (qPCR)
Total RNA was extracted using TRIzol (Invitrogen), and reverse-transcribed using the ExScript RT-PCR Kit (TaKaRa, Shiga, Japan) according to manufacturer's instruction. qPCR was performed with the ABI StepOne Real-Time PCR System (Applied Biosystems, Foster City, CA) and the SYBR Premix Ex Taq Kit (TaKaRa) in accordance with the manufacturer's instructions. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as the internal control. Each sample was analyzed in triplicate. The relative FABP1 mRNA level was calculated by normalization to the endogenous GAPDH mRNA expression prior to comparative analysis using the comparative threshold cycle (2 -∆∆Ct ) method. The respective forward and reverse primers used were 5ʹ-CAAGTTCACCATCACCGCTG-3ʹ and 5ʹ-ATTATGTCGCCGTTGAGTTCG-3ʹ (FABP1), and 5ʹ-TGCACCACCAACTGCTTAGC-3ʹ and 5ʹ-AGCTCAGGGATGACCTTGCC-3ʹ (GAPDH).
Total miRNA form frozen tissues was extracted using the miRNeasy Mini Kit (Qiagen, Hilden, German) and cDNA was synthesized using miScript Reverse Transcription Kit (Qiagen). Expression levels of miR-3941, miR-4517, and miR-4672 were quantified using a miRNA-specifc miScript Primer Assay (Qiagen) in combination with the miScript SYBR Green PCR Kit (Qiagen). SNORD6 (U6 snRNA) was used as an internal control.
Western blotting
Protein (30 μg) was subjected to 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and electrophoretically transferred to a polyvinylidene fluoride membrane (Millipore, Billerica, MA). Protein blots were incubated separately with antibodies against Dicer1 (No. 3363, 1:500, Cell Signaling Technology, Beverly, MA), FABP1 (HPA028275, 1:100, Sigma-Aldrich, St. Louis, MO), or β-actin (1:4000, Sigma-Aldrich), probed with the appropriate alkaline phosphatase-conjugated secondary antibody, and detected using chemiluminescence. Immunoreactive protein bands were visualized by adding CDP-Star reagents (Roche Diagnostics, GmbH). Band signal intensities were quantified using Quantity One densitometric software (Bio-Rad, Hercules, CA).
Cellular steatosis
Sodium palmitate (catalog# P9767) and sodium oleate (catalog# O7501) were obtained from SigmaAldrich. Fat-overloading induction of HepG2 cells was performed mainly according to previously established methods [29] , where cells at 80% confluence were exposed to a mixture of unsaturated (oleate) and saturated (palmitate) long-chain free fatty acids (FFA) at a ratio of 2:1. Fatty acid-free bovine serum albumin (BSA) was used as the control. To assess the influence of miRNAs on cellular steatosis, the cells were treated with FFA mixture after 48-h transfection with miRNA mimics or inhibitors. Following incubation with the FFA mixture, cellular lipid accumulation was measured based on Oil Red O staining and triglyceride (TG) levels. Oil Red O staining Oil Red O staining was performed using standard procedures as previously described [30] . Briefly, HepG2 cells were plated onto glass microscope slides, fixed with 5% paraformaldehyde for 15 minutes, and stained with Oil Red O and hematoxylin.
Biochemical analysis
The levels of cell supernatant alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were determined using a commercial kit (Cat.# 1045-717 and 1055-717, respectively, Shanghai Kehua Bio-Engineering, Shanghai, China) using a HITACHI 7020 automated chemical analyzer (Tokyo, Japan) according to the manufacturer's instructions. Intracellular TG content was determined using a commercial kit (TR0100, Sigma-Aldrich) according to the manufacturer's instructions, and normalized to the protein content by bicinchoninic acid assay (Pierce, Rockford, IL).
Assessment of mitochondrial membrane potential (Δψm)
Changes in Δψm were assessed under a fluorescence microscope using the mitochondria-specific dual-fluorescence probe JC-1 (10 µg/ml, Invitrogen) according to manufacturer's instructions. JC-1 is a ratiometric dye that is internalized as a monomer (green fluorescence, excitation/emission = 485/530 nm) and is concentrated by respiring mitochondria with negative inner membrane potential into J-aggregates (red fluorescence, excitation/emission = 535/590 nm). Consequently, mitochondrial depolarization (i.e., loss of Δψm) is indicated by a decreased red/green fluorescence ratio.
Measurement of cellular adenosine triphosphate (ATP) levels
Intracellular ATP levels were determined using a bioluminescent somatic cell ATP assay kit (SigmaAldrich) according to the manufacturer's instructions. Briefly, cells were mixed with somatic cell ATPreleasing reagent and ATP assay mix. The amount of luminescence emitted from each reaction was measured immediately with a luminometer (Orion II Microplate Luminometer, Berthold Detection Systems); ATP levels in each sample were calculated from ATP standard curves. Data are expressed as nmol ATP per mg protein.
Statistical analysis
The differences between two groups were analyzed using a Student t-test. All values are expressed as the mean ± standard deviation (SD) of triplicate experiments. P < 0.05 was considered statistically significant.
Results
miRNAs downregulated FABP1 gene expression
To investigate whether miRNAs regulate FABP1, we knocked down Dicer1, a key regulator of miRNA processing (Fig. 1A, B) . Dicer1 downregulation significantly elevated the levels of both mRNA (Fig. 1C) and protein (Fig. 1D) FABP1 , indicating that miRNAs can regulate FABP1 expression.
To investigate whether miRNAs directly modulate FABP1, we introduced a luciferase reporter with the wild-type FABP1 3ʹ UTR (pmirGLO-FABP13'UTR) into HepG2 cells and found that FABP1 expression levels were substantially increased (Fig. 1E) , indicating that pmir-GLO-FABP13'UTR might bind to the FABP1-targeting miRNAs, freeing the FABP1 mRNA from endogenous miRNA repression and possibly increasing FABP1 protein expression. These observations suggest that miRNAs modulate FABP1 expression by directly targeting its 3ʹ UTR.
Screening for miRNAs that directly target the FABP1 3ʹ UTR
The TargetScan, RNA22, PicTar, and miRanda miRNA target-prediction tools were used to predict candidate FABP1-targeting miRNAs. A pool of 68 miRNAs that potentially target FABP1 was identified (Table 1 ). HepG2 cells were co-transfected with pmirGLO-FABP13'UTR together with the candidate miRNA mimics, and luciferase activity was measured 48 h after transfection. Seven of the 68 miRNAs, i.e., miR-16, miR-134, miR-490-3p, miR-767-5p, miR-3941, miR-4517, and miR-4672, downregulated the luciferase activity significantly as com- Fig. 2A, B) . Fig. 2C depicts the target sequence location of the seven miRNAs in the FABP1 3ʹ UTR. We subsequently performed serial mutations of these potential sites (Table 2) , and constructed mutant FABP1 3ʹ UTR luciferase reporter plasmids. The luciferase reporter assay showed that miR-3941, miR-4517, and miR-4672 binding site mutations abrogated the suppressor effects. However, miR-16, miR-767-5p, miR-134, and miR-490-3P showed no rescue effect on luciferase activity (Fig. 2D ). Taken together, the results suggest that miR-3941, miR-4517, and miR-4672 can modulate FABP1 by directly targeting the corresponding 3ʹ UTR sites.
miR-3941, miR-4517, and miR-4672 inhibited FABP1 expression
To determine whether miR-3941, miR-4517, and miR-4672 can regulate endogenous FABP1, we treated HepG2 cells with their miRNA mimics or inhibitors and evaluated the FABP1 mRNA and protein levels using qPCR and western blotting, respectively. The miRNA mimics downregulated FABP1 protein levels substantially as compared to the NC (Fig. 3A) . In contrast, silencing the miRNAs significantly increased FABP1 expression (Fig. 3B) . Interestingly, the miRNA mimics and inhibitors did not alter FABP1 mRNA levels significantly compared to the NC (Fig. 3C) , indicating that the three miRNAs predominantly function at translational level. We also examine the clinical relevance of the miR-3941, miR-4517, miR-4672 and FABP1 in human liver tissues. As shown in Fig. 3E -F, specimens expressing low-level FABP1 (1#~12#, 12 cases), exhibited high miR-3941 (66.7%, 8 cases), miR-4517 (58.3%, 7 cases) and miR-4672 (75%, 9 cases) expression, whereas samples with high FABP1 expression (13#~24#, 12 cases) showed low-level miR-3941 (58.3%, 7 cases), miR-4517 (75%, 9 cases) and miR-4672 (83.3%, 10 cases), respectively (each P < 0.05). The results suggest that miR-3941, miR-4517, miR-4672 and FABP1 expression levels were negatively correlated in HepG2 cell line and liver tissues.
miR-3941, miR-4517, and miR-4672 alleviated FFA-induced hepatocyte steatosis
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miR-3941, miR-4517, and miR-4672 expression ameliorated FFA-induced hepatocyte injury
Lipid accumulation in hepatocytes leads to mitochondrial dysfunction, which is regarded as a critical component of NAFLD [25, 32, 33] . we examined HepG2 cell Δψm and ATP levels to investigate the effects of miRNAs on mitochondrial function. The control cells had brightly stained mitochondria that emitted red fluorescence (Fig. 5A) . FFA-treated cells had diffuse green fluorescence in the cytoplasm, indicating dissipation of the Δψm. miRNAtreated cells had substantially increased red fluorescence, indicating recovery of Δψm Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry loss. In contrast, rescue of FABP1 overexpression significantly increased Δψm loss in the miRNA-treated cells. Similar results were obtained for the intracellular ATP levels, which represent mitochondrial function damage and cell injury. The ATP levels in FFA-treated cells were markedly decreased (Fig. 5B) , whereas miRNA mimics significantly increased ATP levels, and rescue of FABP1 overexpression reversed the inhibitory effects on ATP levels. Mitochondrial dysfunction results in hepatocyte injury, for which AST and ALT are regarded as markers. FFA significantly increased AST levels (Fig. 5C ), but had no significant 
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Cellular Physiology and Biochemistry effects on ALT levels (Fig. 5D) , which is consistent with the report by Ding et al [34] .. FFAtreated cells transfected with miR-3941, miR-4517, and miR-4672 mimics had significantly decreased AST levels (Fig. 5C ). As expected, rescue of FABP1 overexpression in cells treated with miR-3941, miR-4517, and miR-4672 mimics yielded opposite results (Fig.  5C ). These findings suggest that miR-3941, miR-4517, and miR-4672 alleviate FFA-induced mitochondrial dysfunction and hepatocyte injury by downregulating FABP1 expression.
Discussion
NAFLD has attracted considerable attention due to its high morbidity. It is characterized by excessive TG accumulation in hepatocytes [35] . Prolonged NAFLD is associated with steatohepatitis, which can result in end-stage liver disease [36, 37] . Increasing evidence indicates that miRNAs are associated with hepatic steatosis by altering lipid metabolism [38, 39] . In vitro cell models and in vivo mouse models have shown that FABP1 plays an important role in regulating hepatic lipid metabolism [17, 18, 19] . Accordingly, we hypothesized that miRNAs may be involved in FABP1-induced hepatic steatosis.
To address this hypothesis, we first knocked down the expression of Dicer1, a key regulator of miRNA processing. Both FABP1 mRNA and protein levels were significantly elevated, indicating that miRNAs regulate FABP1. miRNAs negatively regulate their target mRNAs post-transcriptionally by binding to the 3′ UTR. Further, we found that FABP1 expression levels were substantially increased following transfection with a luciferase [17, 40] . Moreover, the Thr94Ala mutation in the FABP1 gene, which should abolish fatty acid binding, decreases TG levels as compared to that in wild-type cells when incubated with extracellular fatty acids [41] .
In a transgenic mouse model, ablation of the Fabp1 gene impaired the ability of the liver to efficiently import and transfer fatty acids to glycerolipid biosynthesis, resulting in reduced hepatic TG accumulation [42] . These changes were not due to the inability to upregulate fatty acid oxidation or TG synthesis, but rather resulted from decreased rates of hepatic fatty acid uptake and trafficking in the face of short-term (48-h) mobilization of adipose TG stores and increased fatty acid availability [42] . Germline FABP1 −/− mice exhibited decreased hepatic TG content with altered fatty acid uptake kinetics [42] . Interestingly, FABP1 −/− mice had altered saturated fatty acid utilization kinetics, and were protected against "Western" diet-induced obesity and hepatic steatosis [18, 19] . Proteomic screens have revealed that FABP1 is overexpressed in obese subjects with simple steatosis, along with paradoxically decreased expression in the progressive versus mild forms of nonalcoholic steatohepatitis [19] . In the present functional studies, we use an in vitro model of cellular steatosis to elucidate the important role of miR-3941, miR-4672, and miR-4517 in regulating hepatocyte lipid metabolism, where the results confirm that miR-3941, miR-4672, and miR-4517 mimics dramatically reduce FFA-induced lipid accumulation and intracellular TG levels by downregulating FABP1 expression in HepG2 cells. Moreover, it has been well-documented that fat accumulation in hepatocytes can induce liver damage [43, 44] ; our study also shows that miR-3941, miR-4517, and miR-4672 alleviate FFA-induced mitochondrial dysfunction and hepatocyte injury by downregulating FABP1 expression.
In summary, we demonstrate that miR-3941, miR-4672, and miR-4517 ameliorate FFA-induced hepatocyte steatosis and injury by suppressing FABP1 expression. Our study provides new understanding of a molecular mechanism underlying hepatocyte steatosis from the miRNA perspective and suggests that miR-3941, miR-4672, and miR-4517 could be of promising therapeutic value for NAFLD.
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